Abstract
The life cycle of HIV-1 can be affected in different manners by the various classes of antiviral agents. Genetic heterogeneity is a characteristic of this virus, which contributes significantly to the ability of the virus to generate mutations which overcome the efficacy of the drug therapy. The selection of drug resistant mutants in vitro can be readily accomplished by maintaining the virus in a state of sub-optimal growth, regulated by slowly increasing the amount of drug pressure applied. This technique is thought to mimic the consequences of drug therapy in patients. Therefore, in this way, novel compounds can be assessed for their selection profile in order to preview the likelihood of emergence of HIV-1 drug resistance in future clinical trials. In addition, combinations of drugs can be investigated in the same manner.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gao, Q., Gu, Z., Parniak, M.A., et al. (1992) In Vitro Selection of Human Immunodeficiency Virus Type I Resistant to \(3^{-}\)-Azido-\(3^{-}\)-Deoxythymidine and \(2^{-},3^{-}\)-Dideoxynosine. J Virol 66, 12–19
Gao., Q., Gu, Z., Salomon, H., et al. (1994) Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1. Arch Virol 136, 111–122
Richman, D., Shih, C-K., Lowy, I., et al. (1991) Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 88, 11241–11245
Larder, B., Kellam, P., Kemp, S. (1993) Convergent combination therapy can select viable multidrug- resistant HIV-1 in vitro. Nature 365, 451–453
Diallo, K., Brenner B., Oliveira, M., et al.. (2003) The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates. Antimicrob Agents Chemother July, 2376–2379
Wainberg MA, Brenner BG, Turner D. (2005)Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 49(5), 1671–1678,.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Oliveira, M., Brenner, B.G., Wainberg, M.A. (2009). Isolation of Drug-Resistant Mutant HIV Variants Using Tissue Culture Drug Selection. In: Prasad, V.R., Kalpana, G.V. (eds) HIV Protocols. Methods In Molecular Biology™, vol 485. Humana Press. https://doi.org/10.1007/978-1-59745-170-3_29
Download citation
DOI: https://doi.org/10.1007/978-1-59745-170-3_29
Publisher Name: Humana Press
Print ISBN: 978-1-58829-859-1
Online ISBN: 978-1-59745-170-3
eBook Packages: Springer Protocols